Trial Profile
A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Ba 679 BR Respimat® 5 μg and Tiotropium Inhalation Capsule 18 μg in Patients With COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2016
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Mar 2016 Results of pooled analysis of this and other 5 trials (see profiles: 270480, 51486, 270481, 270485 and 60495) published in the Advances in Therapy
- 01 Feb 2010 Results were reported in Respiratory Medicine.
- 30 Aug 2007 Status changed from in progress to completed.